Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma

被引：1
|
作者：
Pottier, C. [1 ]
El Habnouni, C. [1 ]
Kervarrec, T. [2 ,3 ]
Beltran, S. [4 ]
Samimi, M. [1 ,3 ]
机构：
[1] CHRU Tours, Dept Dermatol, Hosp Trousseau, Ave Republ, F-37044 Tours 9, France
[2] CHRU Tours, Dept Pathol, F-37044 Tours 9, France
[3] Univ Tours, INRA, ISP 1282, F-37000 Tours, France
[4] CHRU Tours, Dept Neurol, F-37044 Tours 9, France
来源：
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2022年 / 149卷 / 02期
关键词：
Myasthenia gravis; Immune checkpoint inhibitors; Pembrolizumab; Immune adverse event;
D O I：
10.1016/j.annder.2022.01.002
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：142 / 145
页数：4
相关论文
共 50 条
  • [31] A Case of Myasthenia Gravis Exacerbation in a Patient with Melanoma Treated with Pembrolizumab
    Lau, K. H. Vincent
    Kumar, Aditya
    Yang, Irene
    Nowak, Richard
    NEUROLOGY, 2016, 86
  • [32] Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma Case report
    Chen, Yu-Hsiu
    Liu, Feng-Cheng
    Hsu, Chang-Hung
    Chian, Chih-Feng
    MEDICINE, 2017, 96 (27)
  • [33] De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
    Thakolwiboon, Smathorn
    Karukote, Amputch
    Wilms, Henrik
    ANNALS OF NEUROLOGY, 2019, 86 : S109 - S110
  • [34] NIVOLUMAB-INDUCED MYASTHENIA GRAVIS SYNDROME IN A PATIENT WITH HEPATOCELLULAR CARCINOMA
    Varma, A. V.
    El-Abassi, R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) : 652 - 652
  • [35] De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
    Thakolwiboon, Smathorn
    Karukote, Amputch
    Wilms, Henrik
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (06)
  • [36] Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report
    Szuchan, Charles
    Elson, Leah
    Alley, Evan
    Leung, Kevin
    Camargo, Antonio Lewis
    Elimimian, Elizabeth
    Nahleh, Zeina
    Sadler, Diego
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2020, 4 (03)
  • [37] Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
    Tozuka, Takehiro
    Sugano, Teppei
    Noro, Rintaro
    Takano, Natsuki
    Hisakane, Kakeru
    Takahashi, Satoshi
    Tanaka, Toru
    Kashiwada, Takeru
    Takeuchi, Susumu
    Kunugi, Shinobu
    Minegishi, Yuji
    Saito, Yoshinobu
    Kubota, Kaoru
    Seike, Masahiro
    Gemma, Akihiko
    OXFORD MEDICAL CASE REPORTS, 2018, (11): : 398 - 402
  • [38] Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient
    Hutchinson, Alexander
    Eskens, Danielle
    Chan, Abigail
    Bhargava, Anika
    Bycroft, Ryan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 950 - 953
  • [39] Fatal triad of checkpoint inhibitors: Pembrolizumab induced myasthenia gravis with myositis and myocarditis in a patient with thymoma
    Seker, Demet
    Yildirim, Ahmet
    NEUROLOGY ASIA, 2023, 28 (02) : 439 - 443
  • [40] Pembrolizumab-induced myasthenia gravis: A fatal case report
    March, Katherine L.
    Samarin, Michael J.
    Sodhi, Amik
    Owens, Ryan E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (02) : 146 - 149
12345